PERNIX THERAPEUTICS HOLDINGS, INC. (NASDAQ:PTX) Files An 8-K Results of Operations and Financial Condition

PERNIX THERAPEUTICS HOLDINGS, INC. (NASDAQ:PTX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

Story continues below

Exhibit

Number

Description

99.1 Press Release of Pernix Therapeutics Holdings, Inc. dated July 20, 2017


PERNIX THERAPEUTICS HOLDINGS, INC. Exhibit
EX-99.1 2 dp78546_ex9901.htm EXHIBIT 99.1       Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results   Company Expects to Report Full Quarterly Financial Results and Host Conference Call on July 27,…
To view the full exhibit click here

About PERNIX THERAPEUTICS HOLDINGS, INC. (NASDAQ:PTX)

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

An ad to help with our costs